ATFB
MCID: FML001
MIFTS: 66

Familial Atrial Fibrillation (ATFB)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Familial Atrial Fibrillation

MalaCards integrated aliases for Familial Atrial Fibrillation:

Name: Familial Atrial Fibrillation 12 52 25 58 29 6 15 71
Atrial Fibrillation, Familial 52 25 54
Atfb 12 52
Atrial Fibrillation Autosomal Dominant 52
Autosomal Dominant Atrial Fibrillation 52
Atrial Fibrillation, Familial, 1 71
Auricular Fibrillation 25
Atrial Fibrillation 71

Characteristics:

Orphanet epidemiological data:

58
familial atrial fibrillation
Inheritance: Autosomal dominant;

Classifications:



External Ids:

Disease Ontology 12 DOID:0050650
ICD10 via Orphanet 33 I48.9
Orphanet 58 ORPHA334
UMLS 71 C0004238 C1843687 C3468561

Summaries for Familial Atrial Fibrillation

NIH Rare Diseases : 52 Familial atrial fibrillation is an inherited heart condition that disrupts the heart's rhythm. It is characterized by erratic electrical activity in the heart's upper chambers (the atria), causing an irregular response in the heart's lower chambers (the ventricles). This causes a fast and irregular heartbeat (arrhythmia ). Signs and symptoms may include dizziness, chest pain, palpitations , shortness of breath, or fainting. Affected people also have an increased risk of stroke and sudden death. While complications may occur at any age, some affected people never have associated health problems. Familial atrial fibrillation may be caused by changes (mutations ) in any of various genes , some of which have not been identified. It is most often inherited in an autosomal dominant manner, but autosomal recessive inheritance has been reported.

MalaCards based summary : Familial Atrial Fibrillation, also known as atrial fibrillation, familial, is related to atrial fibrillation and cardiac arrhythmia, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Familial Atrial Fibrillation is MYL4 (Myosin Light Chain 4), and among its related pathways/superpathways are Cardiac conduction and cGMP-PKG signaling pathway. The drugs Methylprednisolone hemisuccinate and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and brain, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 An atrial fibrillation that has material basis in autosomal dominant inheritance of the familial atrial fibrillation (ATFB) genes.

Genetics Home Reference : 25 Familial atrial fibrillation is an inherited abnormality of the heart's normal rhythm. Atrial fibrillation is characterized by episodes of uncoordinated electrical activity (fibrillation) in the heart's upper chambers (the atria), which cause a fast and irregular heartbeat. If untreated, this abnormal heart rhythm (arrhythmia) can lead to dizziness, chest pain, a sensation of fluttering or pounding in the chest (palpitations), shortness of breath, or fainting (syncope). Atrial fibrillation also increases the risk of stroke and sudden death. Complications of atrial fibrillation can occur at any age, although some people with this heart condition never experience any health problems associated with the disorder.

Wikipedia : 74 Familial atrial fibrillation is an autosomal dominant heart condition that causes disruptions in the... more...

Related Diseases for Familial Atrial Fibrillation

Diseases in the Atrial Fibrillation family:

Atrial Fibrillation, Familial, 3 Atrial Fibrillation, Familial, 1
Atrial Fibrillation, Familial, 2 Atrial Fibrillation, Familial, 4
Atrial Fibrillation, Familial, 5 Atrial Fibrillation, Familial, 6
Atrial Fibrillation, Familial, 7 Atrial Fibrillation, Familial, 8
Atrial Fibrillation, Familial, 9 Atrial Fibrillation, Familial, 10
Atrial Fibrillation, Familial, 11 Atrial Fibrillation, Familial, 12
Atrial Fibrillation, Familial, 13 Atrial Fibrillation, Familial, 14
Atrial Fibrillation, Familial, 15 Atrial Fibrillation, Familial, 18
Familial Atrial Fibrillation

Diseases related to Familial Atrial Fibrillation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 165)
# Related Disease Score Top Affiliating Genes
1 atrial fibrillation 32.1 SCN5A SCN4B SCN3B SCN2B PITX2 NUP155
2 cardiac arrhythmia 31.8 SCN5A KCNQ1 KCNJ2 KCNE2
3 heart disease 31.6 SCN5A PITX2 NPPA NKX2-5 KCNQ1 KCNJ2
4 long qt syndrome 31.6 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2 KCNA5
5 congestive heart failure 31.5 SCN5A NPPA KCNQ1 KCNJ2 KCNE2 GATA4
6 ventricular fibrillation, paroxysmal familial, 1 31.5 SCN5A NKX2-5 KCNQ1 KCNE2
7 atrioventricular block 31.3 SCN5A NKX2-5 KCNQ1 KCNE2 GJA5 GATA4
8 sick sinus syndrome 31.2 SCN5A SCN3B NPPA KCNJ2 GJA5
9 familial long qt syndrome 31.0 SCN5A KCNQ1 KCNJ2 KCNE2
10 jervell and lange-nielsen syndrome 1 31.0 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
11 sinoatrial node disease 31.0 SCN5A SCN3B NKX2-5 KCNQ1 KCNJ2 KCNE2
12 wolff-parkinson-white syndrome 31.0 SCN5A NKX2-5 KCNQ1 KCNJ2 KCNE2 GJA5
13 heart septal defect 31.0 PITX2 NPPA NKX2-5 GJA5 GATA6 GATA5
14 long qt syndrome 10 31.0 SCN5A SCN4B KCNQ1 KCNE2
15 atrial heart septal defect 31.0 SCN5A PITX2 NPPA NKX2-5 GJA5 GATA6
16 syncope 31.0 SCN5A NPPA KCNQ1 KCNJ2
17 short qt syndrome 31.0 SCN5A SCN4B SCN3B SCN2B KCNQ1 KCNJ2
18 long qt syndrome 1 31.0 SCN5A SCN4B SCN3B SCN2B NKX2-5 KCNQ1
19 brugada syndrome 30.9 SCN5A SCN4B SCN3B SCN2B NUP155 NKX2-5
20 progressive familial heart block, type ia 30.9 SCN5A GJA5
21 dilated cardiomyopathy 30.9 SCN5A SCN4B SCN2B NPPA NKX2-5 KCNQ1
22 atrial fibrillation, familial, 1 30.9 PITX2 ATFB1
23 patent ductus arteriosus 1 30.8 NKX2-5 GATA6 GATA4
24 cardiac conduction defect 30.2 SCN5A KCNQ1
25 atrial fibrillation, familial, 15 12.8
26 brugada syndrome 7 12.2
27 atrial fibrillation, familial, 11 11.7
28 atrial fibrillation, familial, 12 11.7
29 atrial fibrillation, familial, 13 11.7
30 atrial fibrillation, familial, 14 11.7
31 myasthenic syndrome, congenital, 5 10.8 SCN5A KCNQ1 KCNJ2 KCNE2 KCNA5 GJA5
32 long qt syndrome 6 10.8 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
33 long qt syndrome 13 10.8 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
34 long qt syndrome 5 10.8 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
35 long qt syndrome 9 10.8 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
36 heart conduction disease 10.8 SCN5A SCN3B KCNQ1 KCNJ2 KCNE2 KCNA5
37 andersen cardiodysrhythmic periodic paralysis 10.8 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
38 timothy syndrome 10.8 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
39 long qt syndrome 2 10.8 SCN5A SCN4B SCN3B KCNQ1 KCNJ2 KCNE2
40 long qt syndrome 3 10.8 SCN5A SCN4B SCN3B KCNQ1 KCNJ2 KCNE2
41 long qt syndrome 11 10.8 SCN4B KCNQ1 KCNJ2 KCNE2
42 long qt syndrome 12 10.8 SCN5A SCN4B KCNQ1 KCNE2
43 intrinsic cardiomyopathy 10.8 SCN5A SCN4B NPPA NKX2-5 KCNQ1 KCNJ2
44 catecholaminergic polymorphic ventricular tachycardia 10.8 SCN5A SCN4B SCN3B KCNQ1 KCNJ2 KCNE2
45 double outlet right ventricle 10.8 PITX2 NKX2-5 GJA5 GATA6 GATA5 GATA4
46 progressive familial heart block 10.8 SCN5A NKX2-5 KCNQ1 GJA5
47 atrial standstill 10.8 SCN5A NPPA GJA5
48 brugada syndrome 4 10.8 SCN5A KCNQ1 KCNJ2
49 third-degree atrioventricular block 10.8 SCN5A KCNJ2 GJA5
50 left ventricular noncompaction 10.8 SCN5A NKX2-5 KCNQ1 KCNJ2 GJA5 GATA4

Comorbidity relations with Familial Atrial Fibrillation via Phenotypic Disease Network (PDN): (show top 50) (show all 169)


Accessory Nerve Disease Acquired Polycythemia
Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Conjunctivitis Acute Cor Pulmonale
Acute Cystitis Acute Kidney Failure
Acute Myocardial Infarction Acute Vascular Insufficiency of Intestine
Alcoholic Cardiomyopathy Alcoholic Liver Cirrhosis
Amyloidosis Anemia, Autoimmune Hemolytic
Anthracosis Anxiety
Aortic Aneurysm Aortic Atherosclerosis
Aortic Valve Disease 1 Aortic Valve Disease 2
Aortic Valve Insufficiency Asbestosis
Asthma Atrial Tachyarrhythmia with Short Pr Interval
Atrioventricular Block Bacteremia 2
Basilar Artery Insufficiency Benign Essential Hypertension
Bleeding Disorder, Platelet-Type, 11 Blepharitis
Bronchiectasis Bronchitis
Bronchopneumonia Candidiasis
Cardiac Arrest Cardiac Arrhythmia
Cardiogenic Shock Cerebral Atherosclerosis
Cerebral Degeneration Cerebrovascular Disease
Cholangitis Cholecystitis
Chronic Intestinal Vascular Insufficiency Chronic Pulmonary Heart Disease
Chronic Rheumatic Pericarditis Chronic Ulcer of Skin
Colorectal Cancer Conjunctivitis
Constrictive Pericarditis Coronary Artery Aneurysm

Graphical network of the top 20 diseases related to Familial Atrial Fibrillation:



Diseases related to Familial Atrial Fibrillation

Symptoms & Phenotypes for Familial Atrial Fibrillation

UMLS symptoms related to Familial Atrial Fibrillation:


angina pectoris, edema, chest pain

MGI Mouse Phenotypes related to Familial Atrial Fibrillation:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.07 GATA4 GATA5 GATA6 GJA5 KCNA5 KCNJ2
2 homeostasis/metabolism MP:0005376 9.77 GATA4 GATA5 GATA6 GJA5 KCNA5 KCNE2
3 digestive/alimentary MP:0005381 9.76 GATA4 GATA5 GJA5 KCNE2 KCNJ2 KCNQ1
4 muscle MP:0005369 9.4 GATA4 GATA5 GATA6 GJA5 KCNA5 KCNJ2

Drugs & Therapeutics for Familial Atrial Fibrillation

Drugs for Familial Atrial Fibrillation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 506)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
2
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
3
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
4 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
6
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
7
Ranolazine Approved, Investigational Phase 4 95635-55-5, 142387-99-3 56959
8
carbamide peroxide Approved Phase 4 124-43-6
9
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
10
Atorvastatin Approved Phase 4 134523-00-5 60823
11
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
12
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
13
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
14
Diltiazem Approved, Investigational Phase 4 42399-41-7 39186
15
Dalteparin Approved Phase 4 9005-49-6
16
Thrombin Approved, Investigational Phase 4
17
Propranolol Approved, Investigational Phase 4 525-66-6 4946
18
Verapamil Approved Phase 4 52-53-9 2520
19
Ezetimibe Approved Phase 4 163222-33-1 150311
20
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
21
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
22
Nifedipine Approved Phase 4 21829-25-4 4485
23
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
24
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
25
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
26
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
27
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
28
Ramipril Approved Phase 4 87333-19-5 5362129
29 fluindione Approved, Investigational Phase 4 957-56-2
30
Histamine Approved, Investigational Phase 4 51-45-6 774
31
Antazoline Approved Phase 4 91-75-8 2200
32
Terazosin Approved Phase 4 63590-64-7 5401
33
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
34
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
35
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
36
Pantoprazole Approved Phase 4 102625-70-7 4679
37
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
38
Dipyridamole Approved Phase 4 58-32-2 3108
39
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
40
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
41
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
42
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
43
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
44
Nitric Oxide Approved Phase 4 10102-43-9 145068
45
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
46
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
47 Bemiparin Approved, Investigational Phase 4 91449-79-5
48
Cefpirome Approved Phase 4 84957-29-9 5479539
49
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
50
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757

Interventional clinical trials:

(show top 50) (show all 2789)
# Name Status NCT ID Phase Drugs
1 Rate Control in Atrial Fibrillation: A Randomized, Double-Blind, Crossover Comparison of Carvedilol and Metoprolol Tartrate Unknown status NCT02251509 Phase 4 Carvedilol;Metoprolol tartrate
2 Intensive Statin Therapy Effect on Incidence of Post-Operative Atrial Fibrillation Unknown status NCT02029534 Phase 4 Atorvastatin 20 mg;Atorvastatin 80 mg
3 Low Dose of Diltiazem for Rate Control of Atrial Fibrillation Unknown status NCT00834925 Phase 4 low dose diltiazem
4 A Prospective, Multi-Center, Pilot Study to Compare the Safety and Effectiveness of WATCHMAN Left Atrial Appendage Occlusion Device With Rivaroxaban for Stroke Prevention in Patients With Atrial Fibrillation Unknown status NCT02549963 Phase 4 Rivaroxaban
5 The Efficacy and Safety of Dabigatran Etexilate and Different Intensity Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation Unknown status NCT02646267 Phase 4 standard intensity warfarin;low intensity warfarin;dabigatran etexilate
6 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer: A Controlled, Randomized, Double Blinded Trial Unknown status NCT00724581 Phase 4 Amiodarone
7 Linear Anatomically Versus Focal Electrophysiologically Guided Substrate Ablation in Patients With Persistent Atrial Fibrillation Unknown status NCT00196157 Phase 4
8 Comparison of Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran in Patients With Non-valvular Atrial Fibrillation (RIVAL-AF Study) -Multicenter Randomized Study- Unknown status NCT02331602 Phase 4 Rivaroxaban;Dabigatran
9 N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure Unknown status NCT00692718 Phase 4 Epadel, Eicosapentaenoic acid
10 Randomized Study Comparing Cardioversion vs. Catheter Ablation in Patients With Persistent Atrial Fibrillation Unknown status NCT00196209 Phase 4
11 Catheter Ablation for Atrial Fibrillation: A Multicenter Clinical Trial Unknown status NCT01113294 Phase 4
12 Effects of Vernakalant and Flecainide on Atrial Contractility in Patients With Atrial Fibrillation Unknown status NCT01646281 Phase 4 Vernakalant;Flecainide
13 Left Atrial Ablation of Paroxysmal Atrial Fibrillation With Implantable Loop Recorder Follow Up Study 2 Unknown status NCT01504451 Phase 4
14 Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation Unknown status NCT02145546 Phase 4 Amiodarone;Propafenone;Sotalol
15 Phase Ⅳ Study of CARTO 3D Mapping System vs Conventional Method in AF & VT Unknown status NCT00959205 Phase 4
16 Atrial Fibrillation Therapy: A Multi-Center Clinical Study Unknown status NCT01341353 Phase 4 Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists
17 Additional Linear Ablation Perpendicular to the Pulmonary Vein Isolation Line Reduces the Recurrence Rate of Paroxysmal Atrial Fibrillation (ALA-PAF) Unknown status NCT02637453 Phase 4
18 PV-Isolation for Paroxysmal Atrial Fibrillation: Isolation of the Arrhythmogenic Vein(s) vs. Isolation of All Veins Unknown status NCT00605748 Phase 4
19 The Study of Rosuvastatin for Reduction of Postoperative Paroxysmal Atrial Fibrillation in Patient Undergoing Radiofrequency Catheter Ablation Unknown status NCT02502110 Phase 4 rosuvastatin
20 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
21 The Use of Dabigatran Etexilate in Patients With Atrial Fibrillation After Mitral Valve Prosthetic Replacement Unknown status NCT03183843 Phase 4 Dabigatran Etexilate;Warfarin
22 Test of Efficacy and Safety of the Dual Antiplatelet Therapy Compared to the Combination of Oral Anticoagulant Therapy + Dual Antiplatelet Therapy in Patients With Atrial Fibrillation With Low-moderate Risk Submitted to Coronary Stent Implantation Unknown status NCT01141153 Phase 4 Acetylsalicylic Acid + clopidogrel + acenocoumarol;Acetylsalicylic Acid + clopidogrel
23 Left Atrial Ablation for Paroxysmal Atrial Fibrillation and Hypertension With Implantable Loop Recorder With or Without ROX Coupler Follow Up Study: The LAAPITUP 3 Study Unknown status NCT02243891 Phase 4
24 Randomized Controlled Trial to Evaluate Implanted Event Recorders for the First Diagnosis of Atrial Fibrillation in High-risk Patients Unknown status NCT01461434 Phase 4
25 Efficacy and Safety of Non-vitamin K Oral Anticoagulants and Vitamin K Oral Anticoagulants on Some Metabolic and Coagulation Parameters in Diabetic and Nondiabetic Patients With First Diagnosis of Non-valvular Atrial Fibrillation Unknown status NCT02935855 Phase 4 Dabigatran;Apixaban;Rivaroxaban;Edoxaban;Warfarin;Acenocumarole
26 Safety and Efficacy of Transvenous Pulmonary Isolation for the Treatment of Atrial Fibrillation: A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy Unknown status NCT00773539 Phase 4
27 Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients With Persistent Atrial Fibrillation Unknown status NCT00613496 Phase 4 irbesartan;placebo
28 "Bidirectional Conduction Block of Left Atrial Anterior Line in Patients With Left Atrial Ablation - Reduction of RF Applications Using the Thermocool SmartTouch Contact Force Sensing Catheter Unknown status NCT02217657 Phase 4
29 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
30 Safety of Ticagrelor Plus Warfarin Versus Clopidogrel+Aspirin+Warfarin in Patients With Persistent or Permanent Atrial Fibrillation and Undergoing PCI-S: A Randomized, Open, Controlled, Parallel Group, Multi-center Trial Unknown status NCT02206815 Phase 4 Ticagrelor+Warfarin;Clopidogrel+Aspirin+Warfarin
31 A Randomized, Prospective Multicenter Study to Determine the Incidence of Atrial Fibrillation and Heart Failure in Correlation to Stimulation Modes of Pacemakers Unknown status NCT00161551 Phase 4
32 Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation: A Prospective 2-Centre Randomized Controlled Clinical Study (POWDER-AF) Unknown status NCT02475642 Phase 4
33 AMIOCAAF (AMIOdarone vs. Catheter Ablation for Prevention of Recurrent Symptomatic Atrial Fibrillation): a Randomized Controlled Trial - Vanguard Phase Unknown status NCT02341105 Phase 4 Amiodarone
34 A Randomized, Prospective Multicenter Pilot Study to Determine the Influence of the Ventricular Pacing Site on the Incidence of Atrial Fibrillation and Heart Failure in Patients With Indication for Permanent Pacemaker Stimulation Therapy. Unknown status NCT00292383 Phase 4
35 Dronedarone in Pacemaker Patients With Paroxysmal Atrial Fibrillation Unknown status NCT01070667 Phase 4 Dronedarone;Placebo
36 Atrial Fibrillation and Pericardial Drainage: Incidence of Postoperative Atrial Fibrillation According to the Type of Mediastinal Drainage Catheters Unknown status NCT02808897 Phase 4
37 EvaluAtion of Predictive Value of Multisite Intracardiac EchoCardiography During Imaging of Structure and funCTION of Left Atrial Appendage in Comparison to Transesophageal Echocardiography Unknown status NCT01371279 Phase 4
38 Comparison of Acute Pulmonary Vein (PV) Reconnection Between Contact Force Guided and Blinded PV Isolation in Patients With Symptomatic Atrial Fibrillation Unknown status NCT02924181 Phase 4
39 COR HF - Clinical Benefits in Optimized Remote HF Patient Management Unknown status NCT01482598 Phase 4
40 Comparison of Efficacy and Safety Among DAbigatran, RIvaroxaban, and ApixabaN in Patients HavinG Non-Valvular Atrial Fibrillation in Taiwan (DARING-AF Study) Unknown status NCT02666157 Phase 4 Dabigatran etexilate;Rivaroxaban;Apixaban
41 Comparison of a Rhythm Control Treatment Strategy Versus a Rate Control Strategy in Patients With Permanent or Long-term Persistent Atrial Fibrillation and Heart Failure Treated With Cardiac Resynchronization Therapy - a Pilot Study Unknown status NCT01850277 Phase 4 Amiodarone;Pharmacotherapy to slow and control ventricular rate
42 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
43 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study) Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
44 IntAct, Study on Promotion of Intrinsic Activity. Unknown status NCT00156741 Phase 4
45 Phenprocoumon Versus Dabigatran in Subjects With Atrial Fibrillation and Left Atrial Thrombus - a Prospective, Randomized, Controlled, Open-label One Year Follow-up Pilot Study Unknown status NCT02591225 Phase 4 Dabigatranetexilate;Phenprocoumon
46 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Recently Diagnosed Impaired Left Ventricular Function: a Multicenter, Randomized Controlled Trial Unknown status NCT02509754 Phase 4
47 The Early Diagnosis and Prevention of Ischemic Stroke and Cognition Decline Associated With Coronary Artery Disease Combined With Cerebral Artery Stenosis or Arrhythmia by 24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography Unknown status NCT00247533 Phase 4
48 Intracoronary Stenting and Antithrombotic Regimen: Testing of a Six-week Versus a Six-month Clopidogrel Treatment Regimen in Patients With Concomitant Aspirin and Oral Anticoagulant Therapy Following Drug-eluting Stenting Unknown status NCT00776633 Phase 4 aspirin;clopidogrel;oral anticoagulation
49 Safety of Amiodarone and Ranolazine Together in Patients With Stable Angina Unknown status NCT01558830 Phase 4 ranolazine;placebo
50 Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control Unknown status NCT02025465 Phase 4 Metoprolol;Diltiazem

Search NIH Clinical Center for Familial Atrial Fibrillation

Inferred drug relations via UMLS 71 / NDF-RT 50 :


anisindione
Atenolol
Deslanoside
Digitalis preparation
DIGITALIS,POWDERED
Digitoxin
Digoxin
Diltiazem
Diltiazem Hydrochloride
Diltiazem maleate
Disopyramide
Disopyramide Phosphate
DITIAZ
dofetilide
ibutilide
ibutilide fumarate
Metoprolol
metoprolol succinate
Metoprolol Tartrate
Procainamide
Procainamide Hydrochloride
Propafenone
Propafenone Hydrochloride
Quinidine
quinidine gluconate
quinidine polygalacturonate
Quinidine Sulfate
Sotalol
Sotalol Hydrochloride
Verapamil
Verapamil hydrochloride
Warfarin
Warfarin Sodium
WARFARIN SODIUM ISOPROPANOL COMPLEX

Genetic Tests for Familial Atrial Fibrillation

Genetic tests related to Familial Atrial Fibrillation:

# Genetic test Affiliating Genes
1 Familial Atrial Fibrillation 29

Anatomical Context for Familial Atrial Fibrillation

MalaCards organs/tissues related to Familial Atrial Fibrillation:

40
Heart, Testes, Brain, Kidney, Lung, Endothelial, Liver

Publications for Familial Atrial Fibrillation

Articles related to Familial Atrial Fibrillation:

(show top 50) (show all 103)
# Title Authors PMID Year
1
A novel SCN5A gain-of-function mutation M1875T associated with familial atrial fibrillation. 54 61
18929244 2008
2
Cardiac sodium channel mutation in atrial fibrillation. 54 61
18088563 2008
3
Human KCNQ1 S140G mutation is associated with atrioventricular blocks. 54 61
17467630 2007
4
Atrial fibrillation in KCNE1-null mice. 54 61
15947250 2005
5
Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation. 54 61
15368194 2004
6
KCNQ1 gain-of-function mutation in familial atrial fibrillation. 54 61
12522251 2003
7
Putative role of Brugada syndrome genes in familial atrial fibrillation. 61
31539150 2019
8
Electrophysiologic and molecular mechanisms of a frameshift NPPA mutation linked with familial atrial fibrillation. 61
31077706 2019
9
Characterization and haplotype study of 6 novel STR markers related to the KCNQ1 gene in heterogeneous cardiovascular disorders in the Iranian population 61
30866607 2019
10
A Novel PITX2c Gain-of-Function Mutation, p.Met207Val, in Patients With Familial Atrial Fibrillation. 61
30558760 2019
11
Proarrhythmia in the p.Met207Val PITX2c-Linked Familial Atrial Fibrillation-Insights From Modeling. 61
31695623 2019
12
Molecular Insights into the Short QT Syndrome. 61
31355049 2018
13
A SHOX2 loss-of-function mutation underlying familial atrial fibrillation. 61
30443179 2018
14
Familial clustering of atrial fibrillation and comparative longitudinal outcomes of familial and non-familial atrial fibrillation. 61
28485191 2017
15
Generation and cardiac subtype-specific differentiation of PITX2-deficient human iPS cell lines for exploring familial atrial fibrillation. 61
28677534 2017
16
A frameshift deletion in the sarcomere gene MYL4 causes early-onset familial atrial fibrillation. 61
27742809 2017
17
Prognosis in Familial Atrial Fibrillation. 61
27866163 2016
18
Outcomes Associated With Familial Versus Nonfamilial Atrial Fibrillation: A Matched Nationwide Cohort Study. 61
27866162 2016
19
A novel nonsense mutation in LMNA gene identified by Exome Sequencing in an atrial fibrillation family. 61
27373676 2016
20
Cardiac Delayed Rectifier Potassium Channels in Health and Disease. 61
27261823 2016
21
Clinical Features of Genetic Cardiac Diseases Related to Potassium Channelopathies. 61
27261827 2016
22
A mutation in the atrial-specific myosin light chain gene (MYL4) causes familial atrial fibrillation. 61
27066836 2016
23
Examining rare and low-frequency genetic variants previously associated with lone or familial forms of atrial fibrillation in an electronic medical record system: a cautionary note. 61
25410959 2015
24
NKX2-6 mutation predisposes to familial atrial fibrillation. 61
25319568 2014
25
TNNI3K mutation in familial syndrome of conduction system disease, atrial tachyarrhythmia and dilated cardiomyopathy. 61
24925317 2014
26
Whole-exome sequencing in familial atrial fibrillation. 61
24727801 2014
27
KCNE2 modulates cardiac L-type Ca(2+) channel. 61
24681347 2014
28
Gremlin 2 promotes differentiation of embryonic stem cells to atrial fate by activation of the JNK signaling pathway. 61
24648383 2014
29
In silico investigation of a KCNQ1 mutation associated with familial atrial fibrillation. 61
24411289 2014
30
Pitx2, an atrial fibrillation predisposition gene, directly regulates ion transport and intercalated disc genes. 61
24395921 2014
31
A novel PITX2c loss-of-function mutation associated with familial atrial fibrillation. 61
24333117 2014
32
Selective targeting of gain-of-function KCNQ1 mutations predisposing to atrial fibrillation. 61
24006450 2013
33
Prevalence and spectrum of PITX2c mutations associated with familial atrial fibrillation. 61
23611745 2013
34
Mutations of the SCN4B-encoded sodium channel β4 subunit in familial atrial fibrillation. 61
23604097 2013
35
Characteristics of atrial fibrillation and comorbidities in familial atrial fibrillation. 61
23551519 2013
36
A KCNQ1 mutation causes a high penetrance for familial atrial fibrillation. 61
23350853 2013
37
A novel NKX2.5 loss-of-function mutation responsible for familial atrial fibrillation. 61
23525379 2013
38
A heterozygous variant in the human cardiac miR-133 gene, MIR133A2, alters miRNA duplex processing and strand abundance. 61
23497314 2013
39
Familial atrial fibrillation predicts increased risk of mortality: a study in Danish twins. 61
23255276 2013
40
Polymorphisms but not mutations of the KCNQ1 gene are associated with lone atrial fibrillation in the Chinese Han population. 61
23710137 2013
41
[KCNQ1 mutation in patients with lone atrial fibrillation]. 61
23651960 2013
42
Novel GATA5 loss-of-function mutations underlie familial atrial fibrillation. 61
23295592 2012
43
Novel GATA6 loss-of-function mutation responsible for familial atrial fibrillation. 61
22824924 2012
44
Pro-arrhythmogenic effects of the S140G KCNQ1 mutation in human atrial fibrillation - insights from modelling. 61
22508963 2012
45
Chromosome 4q25 variants are genetic modifiers of rare ion channel mutations associated with familial atrial fibrillation. 61
22818067 2012
46
Mutational spectrum of the GATA5 gene associated with familial atrial fibrillation. 61
22483626 2012
47
Mutations in the potassium channel subunit KCNE1 are associated with early-onset familial atrial fibrillation. 61
22471742 2012
48
The role of atrial natriuretic peptide in modulating cardiac electrophysiology. 61
22083030 2012
49
Prevalence and spectrum of GATA6 mutations associated with familial atrial fibrillation. 61
22257684 2012
50
Characterization of KCNQ1 atrial fibrillation mutations reveals distinct dependence on KCNE1. 61
22250012 2012

Variations for Familial Atrial Fibrillation

ClinVar genetic disease variations for Familial Atrial Fibrillation:

6 (show top 50) (show all 262) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MYL4 NM_002476.2(MYL4):c.31G>A (p.Glu11Lys)SNV Pathogenic 224067 rs886037778 17:45286819-45286819 17:47209453-47209453
2 ABCC9 NM_005691.3(ABCC9):c.-11T>CSNV Conflicting interpretations of pathogenicity 35625 rs72559432 12:22089619-22089619 12:21936685-21936685
3 KCNA5 NM_002234.4(KCNA5):c.898G>A (p.Gly300Ser)SNV Conflicting interpretations of pathogenicity 191462 rs148708451 12:5154211-5154211 12:5045045-5045045
4 KCNA5 NM_002234.4(KCNA5):c.1150G>A (p.Gly384Arg)SNV Conflicting interpretations of pathogenicity 191572 rs76708779 12:5154463-5154463 12:5045297-5045297
5 ABCC9 NM_005691.3(ABCC9):c.2644-11G>ASNV Conflicting interpretations of pathogenicity 35631 rs61926078 12:22005167-22005167 12:21852233-21852233
6 ABCC9 NM_005691.3(ABCC9):c.2770-13A>GSNV Conflicting interpretations of pathogenicity 162686 rs184123387 12:22001193-22001193 12:21848259-21848259
7 ABCC9 NM_005691.3(ABCC9):c.2199-6T>CSNV Conflicting interpretations of pathogenicity 180001 rs535477725 12:22017417-22017417 12:21864483-21864483
8 KCNJ2 NM_000891.2(KCNJ2):c.1229A>G (p.Asn410Ser)SNV Conflicting interpretations of pathogenicity 190804 rs141069645 17:68172409-68172409 17:70176268-70176268
9 ABCC9 NM_005691.3(ABCC9):c.1165-19dupduplication Conflicting interpretations of pathogenicity 45385 rs35857705 12:22063251-22063252 12:21910317-21910318
10 ABCC9 NM_005691.3(ABCC9):c.1557G>A (p.Glu519=)SNV Conflicting interpretations of pathogenicity 45388 rs143346402 12:22059121-22059121 12:21906187-21906187
11 ABCC9 NM_005691.3(ABCC9):c.2862C>T (p.Asp954=)SNV Conflicting interpretations of pathogenicity 45407 rs2291550 12:22001088-22001088 12:21848154-21848154
12 ABCC9 NM_005691.3(ABCC9):c.372T>C (p.Asn124=)SNV Conflicting interpretations of pathogenicity 45410 rs377384557 12:22078910-22078910 12:21925976-21925976
13 ABCC9 NM_005691.3(ABCC9):c.407-14C>ASNV Conflicting interpretations of pathogenicity 45412 rs201279882 12:22070051-22070051 12:21917117-21917117
14 KCNQ1 NM_181798.1(KCNQ1):c.808C>T (p.Arg270Trp)SNV Conflicting interpretations of pathogenicity 52970 rs199472776 11:2608860-2608860 11:2587630-2587630
15 KCNQ1 NM_181798.1(KCNQ1):c.798G>T (p.Lys266Asn)SNV Conflicting interpretations of pathogenicity 67020 rs12720457 11:2608850-2608850 11:2587620-2587620
16 KCNQ1 NM_181798.1(KCNQ1):c.-16616T>CSNV Conflicting interpretations of pathogenicity 138009 rs532941548 11:2466324-2466324 11:2445094-2445094
17 KCNQ1 NM_181798.1(KCNQ1):c.1494C>T (p.Pro498=)SNV Conflicting interpretations of pathogenicity 237226 rs112113213 11:2869077-2869077 11:2847847-2847847
18 KCNJ2 NM_000891.2(KCNJ2):c.1259C>T (p.Pro420Leu)SNV Conflicting interpretations of pathogenicity 264482 rs749707062 17:68172439-68172439 17:70176298-70176298
19 KCNQ1 NM_181798.1(KCNQ1):c.1133+3G>ASNV Conflicting interpretations of pathogenicity 304226 rs374767819 11:2683314-2683314 11:2662084-2662084
20 KCNQ1 NM_181798.1(KCNQ1):c.1133+9C>TSNV Conflicting interpretations of pathogenicity 304227 rs770840921 11:2683320-2683320 11:2662090-2662090
21 KCNQ1 NM_181798.1(KCNQ1):c.870+13C>TSNV Conflicting interpretations of pathogenicity 304220 rs201364493 11:2608935-2608935 11:2587705-2587705
22 ABCC9 NM_005691.3(ABCC9):c.2826T>C (p.Tyr942=)SNV Conflicting interpretations of pathogenicity 201611 rs141025897 12:22001124-22001124 12:21848190-21848190
23 ABCC9 NM_005691.3(ABCC9):c.1332C>T (p.Gly444=)SNV Conflicting interpretations of pathogenicity 308041 rs369830406 12:22061134-22061134 12:21908200-21908200
24 KCNQ1 NM_181798.1(KCNQ1):c.6-7C>TSNV Conflicting interpretations of pathogenicity 304216 rs201682200 11:2549151-2549151 11:2527921-2527921
25 ABCC9 NM_005691.3(ABCC9):c.1659+10T>CSNV Conflicting interpretations of pathogenicity 308040 rs201753781 12:22048199-22048199 12:21895265-21895265
26 ABCC9 NM_005691.3(ABCC9):c.1165-7_1165-6deldeletion Conflicting interpretations of pathogenicity 308043 rs35857705 12:22063252-22063253 12:21910318-21910319
27 KCNA5 NM_002234.4(KCNA5):c.180G>A (p.Ala60=)SNV Conflicting interpretations of pathogenicity 309334 rs376660949 12:5153493-5153493 12:5044327-5044327
28 KCNJ2 NM_000891.2(KCNJ2):c.-228C>TSNV Conflicting interpretations of pathogenicity 324825 rs765064661 17:68165831-68165831 17:70169690-70169690
29 LAMA4 NM_001105206.3(LAMA4):c.3742A>G (p.Ile1248Val)SNV Conflicting interpretations of pathogenicity 488160 rs547323858 6:112454047-112454047 6:112132845-112132845
30 KCNJ2 NM_000891.2(KCNJ2):c.*3353C>TSNV Uncertain significance 324893 rs886053346 17:68175817-68175817 17:70179676-70179676
31 KCNE2 NM_172201.1(KCNE2):c.-121C>TSNV Uncertain significance 339713 rs188625398 21:35736342-35736342 21:34364043-34364043
32 KCNE2 NM_172201.1(KCNE2):c.153G>T (p.Leu51=)SNV Uncertain significance 339718 rs143767851 21:35742930-35742930 21:34370631-34370631
33 KCNE2 NM_172201.1(KCNE2):c.*62G>ASNV Uncertain significance 339719 rs72550218 21:35743211-35743211 21:34370912-34370912
34 KCNE2 NM_172201.1(KCNE2):c.*240G>CSNV Uncertain significance 339720 rs773295544 21:35743389-35743389 21:34371090-34371090
35 KCNJ2 NM_000891.2(KCNJ2):c.*2774_*2775deldeletion Uncertain significance 324880 rs35656864 17:68175206-68175207 17:70179065-70179066
36 KCNJ2 NM_000891.2(KCNJ2):c.*2775dupduplication Uncertain significance 324879 rs35656864 17:68175205-68175206 17:70179064-70179065
37 KCNJ2 NM_000891.2(KCNJ2):c.*2776deldeletion Uncertain significance 324885 rs886053343 17:68175240-68175240 17:70179099-70179099
38 KCNJ2 NM_000891.2(KCNJ2):c.*2812T>CSNV Uncertain significance 324886 rs886053344 17:68175276-68175276 17:70179135-70179135
39 KCNE2 NM_172201.1(KCNE2):c.-52G>ASNV Uncertain significance 339717 rs41314699 21:35736411-35736411 21:34364112-34364112
40 KCNJ2 NM_000891.2(KCNJ2):c.344C>T (p.Ala115Val)SNV Uncertain significance 324831 rs886053323 17:68171524-68171524 17:70175383-70175383
41 KCNJ2 NM_000891.2(KCNJ2):c.*1702dupduplication Uncertain significance 324863 rs886053334 17:68174165-68174166 17:70178024-70178025
42 KCNJ2 NM_000891.2(KCNJ2):c.*2526A>GSNV Uncertain significance 324875 rs886053337 17:68174990-68174990 17:70178849-70178849
43 KCNJ2 NM_000891.2(KCNJ2):c.*2663T>CSNV Uncertain significance 324877 rs886053338 17:68175127-68175127 17:70178986-70178986
44 KCNJ2 NM_000891.2(KCNJ2):c.*2771_*2775deldeletion Uncertain significance 324882 rs35656864 17:68175206-68175210 17:70179065-70179069
45 KCNJ2 NM_000891.2(KCNJ2):c.*2772_*2775deldeletion Uncertain significance 324881 rs35656864 17:68175206-68175209 17:70179065-70179068
46 KCNJ2 NM_000891.2(KCNJ2):c.*124G>ASNV Uncertain significance 324835 rs886053325 17:68172588-68172588 17:70176447-70176447
47 KCNJ2 NM_000891.2(KCNJ2):c.*2698T>CSNV Uncertain significance 324878 rs368668294 17:68175162-68175162 17:70179021-70179021
48 KCNJ2 NM_000891.2(KCNJ2):c.*2754T>CSNV Uncertain significance 324884 rs9915769 17:68175218-68175218 17:70179077-70179077
49 KCNJ2 NM_000891.2(KCNJ2):c.*1440A>TSNV Uncertain significance 324858 rs886053332 17:68173904-68173904 17:70177763-70177763
50 KCNJ2 NM_000891.2(KCNJ2):c.*1631C>GSNV Uncertain significance 324860 rs886053333 17:68174095-68174095 17:70177954-70177954

Expression for Familial Atrial Fibrillation

Search GEO for disease gene expression data for Familial Atrial Fibrillation.

Pathways for Familial Atrial Fibrillation

Pathways related to Familial Atrial Fibrillation according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.42 SCN5A SCN4B SCN3B SCN2B NPPA NKX2-5
2
Show member pathways
12.38 SCN5A SCN4B NPPA MYL4 KCNQ1 GATA4
3 12.17 KCNQ1 KCNJ2 KCNE2 KCNA5
4 11.99 SCN5A SCN4B SCN3B KCNQ1
5
Show member pathways
11.85 SCN5A SCN4B SCN3B SCN2B
6
Show member pathways
11.51 SCN5A SCN4B SCN3B SCN2B KCNQ1 KCNE2
7 11.4 SCN5A NKX2-5 GATA4
8 11.34 MYL4 GATA6 GATA4
9 11.33 PITX2 NKX2-5 GATA6 GATA4
10 11.03 SCN5A SCN4B SCN3B SCN2B
11 11.02 SCN5A SCN4B SCN3B SCN2B KCNQ1 KCNJ2
12 10.95 NPPA NKX2-5 GATA4
13 10.8 KCNQ1 KCNJ2
14 10.28 NPPA NKX2-5 GATA4

GO Terms for Familial Atrial Fibrillation

Cellular components related to Familial Atrial Fibrillation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 voltage-gated potassium channel complex GO:0008076 9.46 KCNQ1 KCNJ2 KCNE2 KCNA5
2 Z disc GO:0030018 9.43 SCN5A SCN3B KCNA5
3 voltage-gated sodium channel complex GO:0001518 9.26 SCN5A SCN4B SCN3B SCN2B
4 intercalated disc GO:0014704 9.02 SCN5A SCN4B KCNJ2 KCNA5 GJA5

Biological processes related to Familial Atrial Fibrillation according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 10.16 SCN5A SCN4B SCN3B SCN2B KCNQ1 KCNJ2
2 potassium ion transport GO:0006813 9.99 KCNQ1 KCNJ2 KCNE2 KCNA5 GJA5
3 potassium ion transmembrane transport GO:0071805 9.95 KCNQ1 KCNJ2 KCNE2 KCNA5
4 sodium ion transport GO:0006814 9.95 SCN5A SCN4B SCN3B SCN2B
5 sodium ion transmembrane transport GO:0035725 9.92 SCN5A SCN4B SCN3B SCN2B
6 regulation of ion transmembrane transport GO:0034765 9.92 SCN5A SCN4B SCN3B SCN2B KCNQ1 KCNJ2
7 cardiac conduction GO:0061337 9.88 SCN5A SCN3B KCNQ1 KCNJ2 KCNE2 GJA5
8 regulation of ventricular cardiac muscle cell membrane repolarization GO:0060307 9.85 SCN5A SCN4B KCNQ1 KCNE2 GJA5
9 cardiac muscle tissue development GO:0048738 9.83 NKX2-5 GATA6 GATA5 GATA4
10 ventricular cardiac muscle cell action potential GO:0086005 9.83 SCN5A SCN3B KCNQ1 KCNE2 GJA5
11 cardiac muscle cell differentiation GO:0055007 9.81 NKX2-5 GATA6 GATA4
12 positive regulation of heart rate GO:0010460 9.81 SCN3B NPPA KCNQ1
13 positive regulation of sodium ion transport GO:0010765 9.81 SCN5A SCN4B SCN3B NKX2-5
14 regulation of sodium ion transmembrane transporter activity GO:2000649 9.8 SCN4B SCN3B SCN2B
15 regulation of atrial cardiac muscle cell membrane depolarization GO:0060371 9.8 SCN5A SCN3B SCN2B GJA5
16 potassium ion export across plasma membrane GO:0097623 9.79 KCNQ1 KCNE2 KCNA5
17 regulation of cardiac muscle cell contraction GO:0086004 9.79 SCN5A KCNJ2 GATA4
18 atrial septum morphogenesis GO:0060413 9.78 NKX2-5 GJA5 GATA4
19 regulation of atrial cardiac muscle cell membrane repolarization GO:0060372 9.78 SCN5A NPPA KCNQ1 KCNA5
20 regulation of membrane repolarization GO:0060306 9.77 KCNQ1 KCNJ2 KCNE2
21 membrane depolarization during cardiac muscle cell action potential GO:0086012 9.77 SCN5A SCN4B SCN3B SCN2B KCNJ2
22 membrane repolarization during action potential GO:0086011 9.76 KCNQ1 KCNJ2 KCNE2
23 intestinal epithelial cell differentiation GO:0060575 9.75 GATA6 GATA5 GATA4
24 regulation of ventricular cardiac muscle cell membrane depolarization GO:0060373 9.74 SCN5A SCN3B GJA5
25 SA node cell action potential GO:0086015 9.72 SCN5A SCN3B GJA5
26 positive regulation of cardioblast differentiation GO:0051891 9.71 NKX2-5 GATA6 GATA4
27 membrane depolarization GO:0051899 9.7 SCN5A SCN3B
28 regulation of cardiac muscle contraction GO:0055117 9.7 NKX2-5 GJA5
29 embryonic heart tube development GO:0035050 9.7 NKX2-5 GJA5
30 cardiac muscle contraction GO:0060048 9.7 SCN5A SCN4B SCN3B SCN2B NKX2-5 MYL4
31 membrane depolarization during action potential GO:0086010 9.69 SCN5A SCN3B
32 cardiovascular system development GO:0072358 9.69 NKX2-5 KCNQ1
33 cell growth involved in cardiac muscle cell development GO:0061049 9.69 NPPA GATA4
34 positive regulation of potassium ion transmembrane transport GO:1901381 9.68 KCNQ1 KCNJ2
35 cardiac muscle hypertrophy in response to stress GO:0014898 9.68 NPPA GATA6
36 membrane repolarization during ventricular cardiac muscle cell action potential GO:0098915 9.68 KCNQ1 KCNE2
37 membrane repolarization GO:0086009 9.68 KCNQ1 KCNE2
38 positive regulation of cardiac muscle contraction GO:0060452 9.67 NPPA KCNQ1
39 membrane repolarization during cardiac muscle cell action potential GO:0086013 9.67 KCNQ1 KCNJ2
40 cardiac ventricle morphogenesis GO:0003208 9.67 NKX2-5 GATA4
41 membrane repolarization during atrial cardiac muscle cell action potential GO:0098914 9.66 KCNQ1 KCNA5
42 cardiac conduction system development GO:0003161 9.66 NKX2-5 GJA5
43 AV node cell action potential GO:0086016 9.65 SCN5A SCN4B
44 atrial cardiac muscle cell action potential GO:0086014 9.65 SCN5A SCN3B NUP155 KCNQ1 KCNA5
45 AV node cell to bundle of His cell communication GO:0086067 9.64 SCN5A GJA5
46 cardiac muscle cell action potential involved in contraction GO:0086002 9.43 SCN5A SCN4B SCN3B SCN2B KCNJ2 KCNE2
47 regulation of heart rate by cardiac conduction GO:0086091 9.28 SCN5A SCN4B SCN3B SCN2B KCNQ1 KCNJ2

Molecular functions related to Familial Atrial Fibrillation according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.93 PITX2 NKX2-5 GATA6 GATA5 GATA4
2 transcription regulatory region DNA binding GO:0044212 9.85 NKX2-5 GATA6 GATA5 GATA4
3 ion channel binding GO:0044325 9.72 SCN5A SCN4B SCN3B KCNQ1 KCNE2
4 potassium channel activity GO:0005267 9.7 KCNQ1 KCNE2 KCNA5
5 voltage-gated potassium channel activity GO:0005249 9.67 KCNQ1 KCNE2 KCNA5
6 scaffold protein binding GO:0097110 9.63 SCN5A KCNQ1 KCNA5
7 sodium channel regulator activity GO:0017080 9.58 SCN4B SCN3B SCN2B
8 inward rectifier potassium channel activity GO:0005242 9.57 KCNJ2 KCNE2
9 voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization GO:1902282 9.56 KCNQ1 KCNE2
10 sodium channel activity GO:0005272 9.56 SCN5A SCN4B